In this free webinar, learn what clinical in-use studies are and why they matter for biologics safety, efficacy and CMC lifecycle. Attendees will gain insight intoIn this free webinar, learn what clinical in-use studies are and why they matter for biologics safety, efficacy and CMC lifecycle. Attendees will gain insight into

Bridging Bench to Bedside: De‑Risking Biotherapeutic Administration via CDMO‑Led Clinical‑Mimic and In‑Use Testing Strategies, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn what clinical in-use studies are and why they matter for biologics safety, efficacy and CMC lifecycle. Attendees will gain insight into designing clinical in-use studies and primary considerations. The featured speakers will discuss analytical method selection for the assessment of critical quality attributes. The speakers will also share compatibility and device considerations (e.g., diluents, IV lines, filters, syringes and infusion bags). Attendees will learn about translating results into labelling, pharmacy SOPs and risk versus benefit decisions.

TORONTO, Jan. 7, 2026 /PRNewswire/ — As biotherapeutics leave the controlled environment of the manufacturing facility and enter real-world clinical trials, the risk of failure due to lack of efficacy could be as high as 50%. This can be de-risked by evaluating how stressors during preparation and administration may affect therapy, using clinical in-use studies during drug product process development.

This webinar explores how clinical mimic studies sit at the intersection of stability, compatibility, handling and patient safety. The featured speakers will focus on the risks of aggregation, adsorption, subvisible particles and functional loss and will introduce considerations that accompany reconstitution, dilution and storage. Real case examples will be presented to highlight common failure modes and mitigation strategies to enable safe and efficient clinical use.

Participants will learn approaches to design robust, fit-for-purpose clinical in-use protocols aligned with evolving regulatory expectations (WHO, FDA, EMA and USP), selection of appropriate physicochemical and biophysical analytical methods and interpretation of data to support decision making and risk management with respect to clinical administration of biotherapeutic drug products.

Register for this webinar to learn how clinical in-use studies contribute to clinical trial success by strengthening the safety, efficacy and reliability of biotherapeutic drug administration.

Join experts from FUJIFILM Biotechnologies, Daniel Pettit, Head of Analytical Development; and Natalia Harasimiuk, Director of Analytical Services, for the live webinar on Thursday, January 22, 2026, at 10am EST (4pm CET/EU-Central).

For more information, or to register for this event, visit Bridging Bench to Bedside: De‑Risking Biotherapeutic Administration via CDMO‑Led Clinical‑Mimic and In‑Use Testing Strategies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit www.xtalks.com
For information about hosting a webinar visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bridging-bench-to-bedside-derisking-biotherapeutic-administration-via-cdmoled-clinicalmimic-and-inuse-testing-strategies-upcoming-webinar-hosted-by-xtalks-302654658.html

SOURCE Xtalks

Market Opportunity
Octavia Logo
Octavia Price(VIA)
$0.016
$0.016$0.016
+14.28%
USD
Octavia (VIA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

US 'Crypto Czar' David Sacks Denies Overdue Term Amid Warren Review

US 'Crypto Czar' David Sacks Denies Overdue Term Amid Warren Review

PANews reported on September 18th that according to Cointelegraph, following scrutiny by several U.S. lawmakers, a spokesperson for David Sacks, the "Czar" of U.S. artificial intelligence and cryptocurrency affairs, refuted claims that he may have exceeded the 130-day term limit for Special Government Employees (SGEs). Sacks' spokesperson told CNBC on Wednesday that he carefully manages the number of days in his SGE term to ensure it does not exceed the limit, and that these days do not need to be consecutive. Previously, US lawmakers, including Massachusetts Senator Elizabeth Warren, questioned whether Sacks had exceeded the term limit for his short-term federal position. The group argued that because Sacks holds the position of "special government employee" (a position with a 130-day annual work limit), he should disclose the number of days he has served since US President Trump's inauguration on January 20. As of Wednesday, 167 work days had passed since Trump's inauguration (excluding US public holidays). To stay within the 130-day limit, Sacks would need to have taken at least 37 days of leave during that time.
Share
PANews2025/09/18 11:06
NuScale Power (SMR) Stock Surges 12% Pre-Market on Bank of America Upgrade

NuScale Power (SMR) Stock Surges 12% Pre-Market on Bank of America Upgrade

TLDR BofA Securities upgraded NuScale Power (NYSE:SMR) from Underperform to Neutral but cut its price target from $34 to $28 The stock has dropped approximately
Share
Blockonomi2026/01/09 21:30
XRP, SHIB, HBAR Among 15 to Get Faster Crypto ETF Approval Under SEC’s New Rule

XRP, SHIB, HBAR Among 15 to Get Faster Crypto ETF Approval Under SEC’s New Rule

The post XRP, SHIB, HBAR Among 15 to Get Faster Crypto ETF Approval Under SEC’s New Rule appeared on BitcoinEthereumNews.com. The U.S. Securities and Exchange Commission (SEC) approves proposed rule changes to adopt generic listing standards for crypto exchange-traded funds (ETFs) filed under the commodity rule by securities exchanges such as Nasdaq. This makes XRP, Shiba Inu (SHIB), and Hedera (HBAR) among 12-15 crypto assets eligible for faster ETF launch. US SEC Passes Generic Listing Standards for Crypto ETFs The U.S. SEC approves generic listing standards for crypto ETFs, according to an official announcement by the commission on September 17. Nasdaq, NYSE, and Cboe can now list and trade commodity-based trust shares of eligible spot commodities, including digital assets, without submitting a 19b-4 form. This reduces the crypto ETF approval timeline from 240 days to 75 days under the Securities Act of 1933. “By approving these generic listing standards, we are ensuring that our capital markets remain the best place in the world to engage in the cutting-edge innovation of digital assets,” said SEC Chairman Paul S. Atkins. U.S. SEC Approves Crypto Generic Listing Standards. Source: SEC “This approval helps to maximize investor choice and foster innovation by streamlining the listing process and reducing barriers to access digital asset products within America’s trusted capital markets,” he added. The generic listing standards provide much-needed regulatory clarity and certainty to the investment community, while ensuring investor protections. Bloomberg ETF analysts Eric Balchunas and James Seyffart expect more than 100 crypto ETFs to launch in the next 12 months. The existing spot crypto ETFs may see accelerated approval in the coming weeks. XRP, SHIB, HBAR Among 15 Top Crypto Eligible for Faster Approval Crypto assets that have futures contract trading on a regulated platform, such as Coinbase, are eligible for faster approval within 75 days. Bloomberg senior ETF analyst Eric Balchunas revealed 12-15 coins that have futures on Coinbase. These include XRP, Shiba…
Share
BitcoinEthereumNews2025/09/18 13:00